MerckVaccines.com | Official Website for Health Care Professionals
WEBAug 16, 2024 · MerckVaccines is a site for health care professionals to find information about Merck's vaccine portfolio, as well as vaccine tools and resources.
Vaccines - Merck.com
WEBWe've been discovering, developing, supplying and delivering vaccines to help prevent disease around the world for over 130 years. It is no secret that inventing and developing vaccines is complex, time intensive and carries no guarantees.
Contact Us | MerckVaccines.com Customer Service - global
WEBContact Merck Vaccines customer service by using the online contact form, calling the Merck Vaccine Customer Contact Center, or use the Callback service to speak to a Vaccine Account Representative.
MMRV Vaccine Family | ProQuad®, M-M-R - mmrv-family-mv
WEBThe MMRV Family of vaccines from Merck includes M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX ® (Varicella Virus Vaccine Live), and ProQuad ® (Measles, Mumps, Rubella, and Varicella Virus Vaccine Live).
U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15 …
WEBJun 22, 2022 · U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children. Clinical data supporting approval demonstrated non-inferior immune responses for all serotypes shared with PCV13 following a four-dose series and superior immune responses for ...
FDA approves Merck vaccine designed to protect adults from
WEBThe Food and Drug Administration on Monday approved Merck's new vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and a lung infection...
Merck Announces V116, an Investigational, 21-valent …
WEBJul 27, 2023 · Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials. Topline results demonstrated V116 elicited positive immune responses in both vaccine-naïve and vaccine-experienced adult patient populations. The 21 serotypes ...
US FDA Approves Merck's Pneumococcal Vaccine for Adults
WEBJun 17, 2024 · Merck currently has two approved pneumococcal shots — Vaxneuvance that is given to six weeks or older individuals and Pneumovax 23 for adults 50 years and older as well as two-year olds...
GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, …
WEBGARDASIL 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.
Merck Announces U.S. FDA Approval of VAXNEUVANCE™ …
WEBJul 16, 2021 · VAXNEUVANCE, Merck’s approved 15-valent pneumococcal conjugate vaccine, consists of purified capsular polysaccharides from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F individually conjugated to CRM 197 carrier protein.